Categories: Technology

Update on the privatisation of Humo payments system in Uzbekistan

| Source: JSC Kaspi.kz

ALMATY, Kazakhstan, Nov. 15, 2024 (GLOBE NEWSWIRE) — In August 2024 we (“Kaspi.kz”) submitted a non-binding letter of interest to Uzbekistan’s State Assets Management Agency (“SAMA”), indicating our interest in participating in the privatisation of the National Interbank Processing Center (“Humo”). At this time, we are not proceeding further in the process.

Uzbekistan’s economy is growing fast and its government is pursuing an attractive reform agenda. Kaspi.kz’s innovative digital products improve the everyday lives of consumers and merchants and we will continue to look for opportunities to play a part in Uzbekistan’s exciting digital transformation.

Contacts

David Ferguson
david.ferguson@kaspi.kz
+44 7427 751 275

About Kaspi.kz

Kaspi.kz’s mission is to improve people’s lives by developing innovative mobile products and services. To deliver upon this we operate a unique two-sided Super App model – Kaspi.kz Super App for consumers and Kaspi Pay Super App for merchants.

Through these Super Apps consumers and merchants can access our leading Payments, Marketplace, and Fintech Platforms. All our services are designed to be highly relevant to users’ everyday needs and enable consumers and merchants to connect and transact, using our proprietary payments network.

The combination of a large, highly engaged consumer and merchant base, best-in-class, highly relevant digital products and a capex lite approach, results in strong top-line growth, a profitable business model and enables us to continue innovating, delighting our users and fulfilling our mission.

Harvard Business School has written two case studies on Kaspi.kz which it continues to teach to its MBA students.

Kaspi.kz has been listed on Nasdaq since January 2024.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws, which statements relate to our current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “upcoming”, “believe,” “will,” “expect,” “plan,” “opportunity” or other similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, risks related to the following: the growth of the Uzbek economy; our ability to attract sufficient new customers, engage and retain our existing customers or sell additional functionality, products and services to them on our platforms; our ability to maintain and improve the network effects of our Super App business model; our ability to improve or maintain technology infrastructure; our ability to successfully execute the new business model and reach profitability of the e-Grocery operations; our ability to partner with sufficient new merchants or maintain relationships with our existing merchant partners; our ability to effectively manage the growth of our business and operations; developments affecting the financial services industry; our brand or trusted status of our platforms and Super Apps; our ability to retain and motivate our personnel and attract new talent, or to maintain our corporate culture; our ability to keep pace with rapid technological developments to provide innovative services; our ability to implement changes to our systems and operations necessary to capitalize on our future growth opportunities; changes in relationships with third-party providers, including software and hardware suppliers, delivery services, credit bureaus and debt collection agencies; our ability to compete successfully against existing or new competitors; our ability to integrate acquisitions, strategic alliances and investments; our ability to adequately obtain, maintain, enforce and protect our intellectual property and similar proprietary rights; evolving nature of Kazakhstan’s legislative and regulatory framework; our ability to obtain or retain certain licenses, permits and approvals in a timely manner; our ability to successfully remediate the existing material weaknesses in our internal control over financial reporting and our ability to establish and maintain an effective system of internal control over financial reporting; dependence on our subsidiaries for cash to fund our operations and expenses, including future dividend payments, if any; and risks related to other factors discussed under “Risk Factors” in the annual report on Form 20-F filed with the U.S. Securities and Exchange Commission on 29 April 2024.

We operate in an evolving environment. New risks emerge from time to time, and it is not possible for our management to predict all risks, nor can we assess the effect of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

GlobeNews Wire

Recent Posts

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI Enabling Technologies Outreach in Japan and to Advance Glycan Production

TAIPEI, Taiwan, Dec. 23, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global…

3 hours ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include…

3 hours ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include…

3 hours ago

MaxCyte Announces Retirement of Board Member Art Mandell

December 23, 2024 02:00 ET  | Source: MaxCyte, Inc ROCKVILLE, Md., Dec. 22, 2024 (GLOBE…

3 hours ago

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic…

3 hours ago

AllNew 2025 Kia K4 Earns 2024 IIHS Top Safety Pick Award

New compact sedan adds to its list of attributes by being recognized for occupant protection…

7 hours ago